Theodore S. Hong, MD of Massachusetts General Hospital discusses the Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer at ASCO GI 2017
Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer
